Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + EGFR TKIs in EGFR-Resistant Advanced NSCLC
NCT04007835Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04007835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007835.